Mobile App

Google Play Apple Store
Podcasts in Advanced Newly Diagnosed Multiple Myeloma: Updates from EHA 2024
These are exciting times in the therapeutic landscape of multiple myeloma (MM) due to introduction of quadruplet regimens, novel therapies, and rapid updates to existing treatment paradigms. It is crucial that healthcare professionals are well-aware of new evidence and have the knowhow to incorporate updates into their respective practices. This activity is designed to aid busy clinicians in staying abreast of recent insights into safely integrating monoclonal antibody-based quadruplet and triplet regimens in the first-line treatment of diverse patients with newly diagnosed MM (NDMM).

This podcast will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.
Review the activity to claim AMA/ABS/ANCC/ACPE credit after completion of the brief Post-Test/Evaluation(s).

Peter Voorhees, MD Peter Voorhees, MD
Clinical Professor, Hematology and Oncology
Wake Forest University School of Medicine

*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2024 EHA Annual Congress.
Supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Launch Date: June 17, 2024
Release Date: June 17, 2024
Expiration Date: May 31, 2025

Mini Module


Change Settings